Expression of miR-497/195 in BCP-ALL xenograft and diagnostic samples. (A) Expression of miR-497/195 in an extended cohort of 55 pdx samples with TTL^short and TTL^long phenotypes assessed by qRT-PCR. Expression relative to healthy donor peripheral blood mononuclear cells compared between subgroups as indicated (Mann-Whitney U test, horizontal lines). (B) Expression of miR-497/195 in 55 pdx samples from patients who had early relapse, late relapse, or no relapse. (C) Time to leukemia onset (weeks) of NOD/SCID mice transplanted with patient cells, with high (upper quartile) or low (lower quartile) expression of miR-497/195 detected in the respective pdx samples. Expression of miR-497/195 is measured as log₁₀ miR-497 + log₁₀ miR-195 (log-rank test). (D) Expression of miR-497 and miR-195 in an independent cohort of 70 pediatric BCP-ALL diagnostic samples from patients with early, late, or no event (relapse or death in complete remission) assessed by TaqMan arrays.¹⁴ Expression relative to the mean of all the samples compared between subgroups as indicated (Mann-Whitney U test, horizontal lines). (E) Event-free survival of an independent cohort of patients with high (n = 17, upper quartile) or low (n = 17, lower quartile) expression of miR-497/195. Relapse and death in complete remission were included as “event” (log-rank test). (F) Relapse-free survival of 52 patients in an additional patient cohort, with high and low expression of miR-497/195 (above or below median). Expression of miR-497/195 is measured as log₁₀ miR-497 + log₁₀ miR-195 (log-rank test). Data are presented as mean ± standard error of the mean (SEM), in survival curves mean survival (%) ± SEM is indicated.